SEC Comment Letter 0000000000-23-005346 to Longevity Health Holdings, Inc. (XAGE)
Longevity Health Holdings, Inc.
Date: May 18, 2023 · CIK: 0001842939 · Accession: 0000000000-23-005346
AI Filing Summary & Sentiment
File numbers found in text: 333-269773
Show Raw Text
United States securities and exchange commission logo
May 18, 2023
Rajiv Shukla
Chief Executive Officer
ALPHA HEALTHCARE ACQUISITION CORP III
1177 Avenue of the Americas, 5th Floor
New York, New York 10036
Re:ALPHA HEALTHCARE ACQUISITION CORP III
Amendment No. 2 to Registration Statement on Form S-4
Filed May 5, 2023
File No. 333-269773
Dear Rajiv Shukla:
We have reviewed your amended registration statement and have the following
comments. In some of our comments, we may ask you to provide us with information so we
may better understand your disclosure.
Please respond to this letter by amending your registration statement and providing the
requested information. If you do not believe our comments apply to your facts and
circumstances or do not believe an amendment is appropriate, please tell us why in your
response.
After reviewing any amendment to your registration statement and the information you
provide in response to these comments, we may have additional comments. Unless we note
otherwise, our references to prior comments are to comments in our April 3, 2023 letter.
Amendment No. 2 to Registration Statement on Form S-4
Proposal 1: The Business Combination Proposal
Interests of the Sponsor and ALPA's Directors and Officers in the Business Combination , page
98
1.We note your response to comment 6 and reissue the comment. We note that you now
state on page 98 that the Board noted that the interests of the Sponsor “has been materially
altered in the following respects” and then you go on to discuss those alterations. Please
revise to clarify how the Board considered the Sponsor’s interests and other conflicts of
interest in negotiating and recommending the business combination.
FirstName LastNameRajiv Shukla
Comapany NameALPHA HEALTHCARE ACQUISITION CORP III
May 18, 2023 Page 2
FirstName LastName
Rajiv Shukla
ALPHA HEALTHCARE ACQUISITION CORP III
May 18, 2023
Page 2
Equity Line of Credit (ELOC) Financing Agreement, page 115
2.We note that in May 2023, you entered into a Letter of Intent for a Common Stock
Purchase Agreement with an Investor. Please revise your Background of the Business
Combination section to disclose any discussions about the need to obtain additional
financing for the combined company in connection with the Business Combination
transaction or shortly thereafter, including the ELOC, and, as applicable, the
negotiation/marketing processes. Please also revise your disclosure here to include all
material terms of the ELOC, including any termination provisions for the investor.
Finally, please file the ELOC Agreement, Letter of Intent as well as the Registration
Rights Agreement as exhibits to the proxy/registration statement or advise.
Material U.S. Federal Income Tax Consequences , page 116
3.We note your response to comment 7 and we reissue the comment. We note your revised
disclosure on page 120 stating “[e]xcept as otherwise noted, the following discussion is
based upon the Merger being a reorganization within the meaning of section 368(a) of the
Code” and your statement that “[i]f the Merger qualifies as a reorganization within the
meaning of section 368(a) of the Code, a U.S. Holder will generally not recognize gain or
loss for U.S. federal income tax purposes…” Please revise your prospectus disclosure to
provide a firm conclusion regarding treatment of the transaction under Section 368(a) and
remove language stating that certain material tax consequences will “generally” apply. In
addition, please clearly state that the conclusion is the opinion of counsel. Please also
remove any statement that assumes the material tax consequences at issue (e.g., "If the
Merger qualifies as a reorganization within the meaning of Section 368(a) of the Code").
To the extent the opinion is subject to uncertainty, counsel may provide a "should' or
"more likely than not" opinion and explain why a "will" opinion cannot be given and
describe the degree of uncertainty. For guidance, please refer to Sections III.B.2, III.C.3.
and III.C.4 of Staff Legal Bulletin No. 19.
You may contact Michael Fay at 202-551-3812 or Brian Cascio at 202-551-3676 if you
have questions regarding comments on the financial statements and related matters. Please
contact Jessica Ansart at 202-551-4511 or Celeste Murphy at 202-551-3257 with any other
questions.
Sincerely,
Division of Corporation Finance
Office of Industrial Applications and
Services
cc: Laurie Burlingame, Esq.